

# Hemophilia A Treatment Market to hit US\$ 13.3 billion by 2031, (CAGR of 5%)

*Hemophilia A Treatment Market Overview  
2025: Regional Breakdown*

AUSTIN, TX, UNITED STATES, December 4, 2025 /EINPresswire.com/ -- Market Size and Forecasting

According to DataM Intelligence, According to market estimates, the [Hemophilia A Treatment Market](#) generated US\$ 9.1 billion in revenue in 2022 and is poised to attain US\$ 13.3 billion by 2031, reflecting a compound annual growth rate of 5% over the 2024–2031 period.



The rapid shift toward gene therapy, extended half-life (EHL) factor VIII products, and non-factor therapy (e.g., bispecific monoclonal antibodies) is transforming the Hemophilia A treatment landscape. Increased diagnosis rates, newborn screening programs, and reimbursement support in advanced economies are boosting treatment accessibility.

“

United States Hemophilia A Treatment Market Report: Latest Industry Insights”  
*DataM Intelligence 4Market Research LLP*

Hemophilia A results from Factor VIII deficiency, which causes prolonged bleeding. Treatment advancements aim to eliminate recurring infusions and bleeding episodes, improve patient quality of life, and reduce long-term healthcare burden.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):–

<https://www.datamintelligence.com/download-sample/hemophilia-a-treatment-market>

## Growth Drivers

1. Over 220,000 people globally live with Hemophilia A, with 55% classified as moderate to

severe, creating sustained demand for high-efficacy therapies.

Non-factor therapies reduced annual bleed rates (ABR) by up to 90% in clinical trials, accelerating adoption.

2. Gene therapy approvals and late-stage pipelines exceed USD 4 billion in investments from leading biopharma companies.

3. Government funding and newborn screening increased early diagnosis rates by 35% between 2019–2024.

4. Home infusion programs and digital hemophilia care platforms increased therapy adherence by up to 40%.

## Market Segmentation Analysis

### By Therapy Type

Factor VIII Replacement Therapy holds 48% market share (USD 5.95 billion in 2024) but will reduce to 38% by 2032 due to rising adoption of innovative therapies.

Non-Factor Therapy (Bispecific Antibodies) represents 32% (USD 3.97 billion) and will reach USD 13.4 billion by 2032, driven by reduced infusion frequency and high safety profile.

Gene Therapy currently holds 10% share (USD 1.24 billion) but is forecast to grow at the fastest CAGR of 31%, exceeding USD 8.5 billion by 2032.

Others (Antifibrinolytics & Adjunct Therapies) account for the remaining 10%, reaching USD 2.4 billion by 2032.

### By Treatment Regimen

Prophylaxis dominates with 65% share (USD 8.06 billion) and will further rise to 73% by 2032 due to ABR reduction and payer support.

On-Demand Therapy holds 35% (USD 4.34 billion) but will drop to 27% by 2032 as prophylaxis becomes standard for moderate–severe patients.

### By Distribution Channel

Hospital Pharmacies – 52%

Specialty Clinics – 32%

Online Pharmacies – 16% (fastest-growing due to tele-hematology and reimbursement integration)

Request for Customized Sample Report as per Your Business Requirement:  
<https://www.datamintelligence.com/customize/hemophilia-a-treatment-market>

## Regional Insights

### United States

The U.S. Hemophilia A Treatment Market was USD 5.2 billion in 2024, projected to reach USD 12.9 billion by 2032 at 12.1% CAGR.

Medicaid and private insurers expanded coverage for gene therapy and non-factor therapy.

Over 80 hemophilia treatment centers (HTCs) enhance early diagnosis and long-term patient monitoring.

FDA registered 15 ongoing clinical trials for Hemophilia A gene therapy in 2024.

### Japan

Japan's market was USD 720 million in 2024, expected to reach USD 1.82 billion by 2032 at 12.3% CAGR.

National insurance covers 70% of prophylaxis therapy cost.

Growing adoption of subcutaneous non-factor therapy for pediatric patients.

Digital hemophilia monitoring apps reduced emergency admissions by 27%.

### Key Players

According to DataM Intelligence, the Hemophilia A Treatment Market is highly competitive and research-intensive, dominated by global pharmaceutical leaders and emerging gene therapy developers.

Roche | Bayer | Takeda Pharmaceuticals | CSL Behring | Pfizer | BioMarin | Sanofi | Novo Nordisk | Freeline Therapeutics | Spark Therapeutics

### Key Highlights

. Roche's Hemlibra crossed USD 6.4 billion in global revenue in 2024, driven by fast adoption among children and adults.

. BioMarin's gene therapy Valoctocogene Roxaparvovec surpassed USD 850 million in its first commercial year (2024).

. Takeda announced Phase III success of EHL Factor VIII with 60% higher half-life in patients with severe Hemophilia A.

. CSL Behring expanded plasma-derived manufacturing capacity by 30% to meet global demand.

## Recent Developments

1. Pfizer & Spark Therapeutics initiated a long-term real-world study for gene therapy durability (March 2025).

2. Roche received FDA approval for Hemlibra in neonatal prophylaxis (January 2025).

3. Bayer partnered with digital health firm myHemo™ for patient monitoring and therapy adherence (December 2024).

4. Sanofi launched a biosimilar FVIII targeting cost-sensitive markets in LATAM & APAC (October 2024).

## Market Outlook and Opportunities

1. Non-factor therapy to represent 45% of market share by 2032

2. Gene therapy to eliminate the need for lifelong infusion for 15–20% of eligible patients

3. Digital hemophilia management platforms to become a USD 900+ million opportunity by 2032

Asia Pacific forecast as the fastest-growing regional market (14.8% CAGR) due to improved reimbursement and screening policies

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): <https://www.datamintelligence.com/buy-now-page?report=hemophilia-a-treatment-market>

## Conclusion

The Global Hemophilia A Treatment Market is evolving rapidly due to the shift from traditional factor VIII therapy toward non-factor therapy and gene therapy, delivering long-term bleeding control, better patient convenience, and reduced healthcare burden. Supported by major

biopharma investments, government screening initiatives, and clinical innovation, Hemophilia A treatment is positioned for sustained, high-value growth through 2032.

## Related Reports

[Hemophilia B Market - Global Forecast 2024-2032](#)

[Rare Disease Therapeutics Market Share and Pipeline Innovation Report](#)

Sai Kiran

DataM Intelligence 4market Research LLP

+ +1 877-441-4866

sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/872390450>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.